Acyclovir

Research use only, not for human use.

An antiviral agent that competitively inhibits and inactivates HSV-specified DNA polymerases preventing further viral DNA synthesis without affecting the normal cellular processes.

An antiviral agent that competitively inhibits and inactivates HSV-specified DNA polymerases preventing further viral DNA synthesis without affecting the normal cellular processes; primarily used for the treatment of HSV infections.HSV Infection Approved(In Vitro):Acyclovir (Aciclovir, 3-100 μM; 24-72 hours; Jurkat, U937, and K562 leukemia cells) reduces cell viability in a dose- and time-dependent.Acyclovir (Aciclovir, 10-100 μM; 24-72 hours; Jurkat cells) blocks DNA synthesis, thereby arresting the cell cycle in G2/M and S phases and increasing the sub-G1 hypodiploid peak in a dose-dependent manner.Acyclovir (Aciclovir, 10-100 μM; 24-72 hours; Jurkat cells) induces apoptosis through activates caspase-3 and presences nuclear DNA fragmentation.(In Vivo):Acyclovir (20 mg/kg; p.o.; three times daily; for 10 days; BALB/c mice) treatment in infected mice suppresses the development of skin lesions and results in a dissociation between DTH response and antibody production.

Acyclovir (Aciclovir, 3-100 μM; 24-72 hours; Jurkat, U937, and K562 leukemia cells) reduces cell viability in a dose- and time-dependent.?Acyclovir (Aciclovir, 10-100 μM; 24-72 hours; Jurkat cells) blocks DNA synthesis, thereby arresting the cell cycle in G2/M and S phases and increasing the sub-G1 hypodiploid peak in a dose-dependent manner.Acyclovir (Aciclovir, 10-100 μM; 24-72 hours; Jurkat cells) induces apoptosis through activates caspase-3 and presences nuclear DNA fragmentation. Cell Viability Assay Cell Line:Jurkat, U937 and K562 leukemia cells Concentration:3, 10, 30 and 100 μM Incubation Time:24, 48 and 72 hours Result:Showed a dose- and time-dependent reduction of cell viability.Apoptosis Analysis Cell Line:Jurkat cells Concentration:10 and 100 μM Incubation Time:24, 48 and 72 hours Result:Increased of caspase-3 activity and cleavaged the internucleosomal DNA.Cell Cycle Analysis Cell Line:Jurkat cells Concentration:10 and 100 μM Incubation Time:24, 48 and 72 hours Result:Revealed a dose-dependent accumulation of cells in S phase after 24 and 48 h. Showed a dose-dependent increase of the sub-G1 hypodiploid peak after 72 h.

Acyclovir (20 mg/kg; p.o.; three times daily; for 10 days; BALB/c mice) treatment in infected mice suppresses the development of skin lesions and results in a dissociation between DTH response and antibody production. Animal Model:Specific-pathogen-free BALB/c mice (7-week-old) infected with HSV-1 Dosage:20 mg/kg Administration:Oral administration; three times daily; for 10 days Result:Suppressed the development of skin lesions and resulted in a dissociation between DTH response and antibody production.

Aciclovir | Acycloguanosine

Microbiology/Virology

HSV

DNAsynthesis

Infection

HSV Infection

59277-89-3

225.2046

C8H11N5O3

>98% (HPLC)

10 mM in DMSO

NC1=NC(=O)C2=C(N1)N(COCCO)C=N2

6H-Purin-6-one, 2-amino-1,9-dihydro-9-[(2-hydroxyethoxy)methyl]-

(-20℃)

With Ice Pack

≥ 2 years